AR038369A1 - Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto - Google Patents
Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y productoInfo
- Publication number
- AR038369A1 AR038369A1 ARP030100268A ARP030100268A AR038369A1 AR 038369 A1 AR038369 A1 AR 038369A1 AR P030100268 A ARP030100268 A AR P030100268A AR P030100268 A ARP030100268 A AR P030100268A AR 038369 A1 AR038369 A1 AR 038369A1
- Authority
- AR
- Argentina
- Prior art keywords
- trifluoromethyl
- drug
- microns
- benzyl
- drops
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 7
- 229940079593 drug Drugs 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 239000007962 solid dispersion Substances 0.000 title abstract 3
- 238000005507 spraying Methods 0.000 title 1
- 238000001035 drying Methods 0.000 abstract 5
- 229920000642 polymer Polymers 0.000 abstract 4
- -1 3,5-bis-trifluoromethyl-benzyl Chemical group 0.000 abstract 3
- 230000002708 enhancing effect Effects 0.000 abstract 3
- 239000012527 feed solution Substances 0.000 abstract 3
- 239000011236 particulate material Substances 0.000 abstract 2
- 239000000243 solution Substances 0.000 abstract 2
- JRBOFAXVGHMLMM-APWZRJJASA-N (2r,4s)-4-[[3,5-bis(trifluoromethyl)phenyl]methyl-methoxycarbonylamino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2h-quinoline-1-carboxylic acid Chemical compound COC(=O)N([C@H]1C[C@H](N(C2=CC=C(C=C21)C(F)(F)F)C(O)=O)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JRBOFAXVGHMLMM-APWZRJJASA-N 0.000 abstract 1
- GZILZCCGDNKAAV-UHFFFAOYSA-N 5-chloro-1h-indole-2-carboxamide Chemical compound ClC1=CC=C2NC(C(=O)N)=CC2=C1 GZILZCCGDNKAAV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 238000000889 atomisation Methods 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000001694 spray drying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Glanulating (AREA)
- Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Disintegrating Or Milling (AREA)
Abstract
Dispersiones sólidas amorfas homogéneas de fármacos en polímeros mejoradores de la concentración se preparan en tamanos de partícula más grandes adecuados con mínimo contenido de fines, utilizando un atomizador y condiciones de procedimiento capaces de producir gotas que tienen un diámetro medio de al menos 50 micrones y un D10 de al menos 10 micrones. Reivindicación 1: Un procedimiento para producir una composición farmacéutica, caracterizado porque comprende las etapas de: (a) formar una disolución de alimentación que comprende un fármaco, un polímero mejorador de la concentración y un disolvente; (b) dirigir dicha disolución de alimentación hacia un aparato de secado por pulverización que comprende una cámara de secado, medios de atomización para atomizar en gotas dicha disolución de alimentación en dicha cámara de secado, una fuente de gas de secado calentando para secar dichas gotas y medios de recogida del producto secado; (c) atomizar en gotas dicha disolución de alimentación en dicha cámara de secado mediante dichos medios de atomización, teniendo dichas gotas un diámetro medio de al menos 50 micrones y un D10 de al menos 10 micrones; (d) poner en contacto dichas gotas con dicho gas de secado calentado para preparar materiales en partículas de una dispersión sólida amorfa de dicho fármaco y dicho polímero mejorador de la concentración; y (e) recoger dichos materiales en partículas: en el que dicho polímero mejorador de la concentración está presente en dicha disolución en una cantidad suficiente, de manera que dicha dispersión sólida amorfa proporciona una mejora de la concentración de dicho fármaco en un medio de utilización con respecto a una composición testigo que consiste esencialmente en una cantidad equivalente de dicho fármaco solo. Reivindicación 9: El procedimiento según la reivindicación 1, caracterizado porque dicho fármaco se elige del grupo que consta [R-(R*S*)]-5-cloro-N-2-hidroxi-3-{metoximetilamino}-3-oxo-1-(fenilmetil)propil-1H-indol-2-carboxamida, [(1S)-bencil-(2R)-hidroxi-3-((3R,4S)-dihidroxi-pirrolidin-1-il)-3-oxipropil]amida del ácido 5-cloro-1H-indol-2-carboxílico, éster isopropílico del ácido [2R,4S]-4-[acetil(3,5-bis-trifluorometil-bencil)-amino]-2-etil-6-trifluorometil-3,4-dihidro-2H-quinolin-1-carboxílico, éster etílico del ácido [2R,4S]-4-(3,5-bis-trifluorometil-bencil)-metoxicarbonil-amino]-2-etil-6-trifluorometil-3,4-dihidro-2H-quinolin-1-carboxílico y éster isopropílico del ácido [2R,4S]-4-[(3,5-bis-trifluorometil-bencil)-metoxicarbonil-amino]-2-etil-6-trifluorometil-3,4-dihidro-2H-quinolin-1-carboxílico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35398602P | 2002-02-01 | 2002-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038369A1 true AR038369A1 (es) | 2005-01-12 |
Family
ID=27663274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100268A AR038369A1 (es) | 2002-02-01 | 2003-01-30 | Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7780988B2 (es) |
| EP (1) | EP1469830A2 (es) |
| JP (1) | JP2005523260A (es) |
| KR (1) | KR100758045B1 (es) |
| CN (1) | CN1787808A (es) |
| AR (1) | AR038369A1 (es) |
| AU (1) | AU2003239463B2 (es) |
| BR (1) | BR0307515A (es) |
| CA (1) | CA2474958A1 (es) |
| GT (1) | GT200300024A (es) |
| MX (1) | MXPA04007435A (es) |
| PA (1) | PA8565401A1 (es) |
| PE (1) | PE20030804A1 (es) |
| PL (1) | PL371593A1 (es) |
| RS (1) | RS67304A (es) |
| RU (1) | RU2288703C2 (es) |
| TW (1) | TW200404576A (es) |
| UY (1) | UY27645A1 (es) |
| WO (1) | WO2003063821A2 (es) |
| ZA (1) | ZA200405971B (es) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10026698A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
| PL371593A1 (en) | 2002-02-01 | 2005-06-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| WO2003063822A2 (en) | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| CL2004001884A1 (es) * | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
| US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
| US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
| DK1641438T3 (da) | 2004-06-01 | 2010-06-07 | Teva Gyogyszergyar Zartkoeruen | Fremgangsmåde til fremstilling af den amorfe form af et lægemiddel |
| NZ587549A (en) | 2004-06-24 | 2012-10-26 | Vertex Pharma | 6-Amino-indole derivatives and processes for their preparation |
| WO2006060615A1 (en) | 2004-12-01 | 2006-06-08 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg | Non-hygroscopic and powdery amorphous pimecrolimus |
| US9265731B2 (en) * | 2005-01-28 | 2016-02-23 | Bend Research, Inc. | Drying of drug-containing particles |
| US20070026073A1 (en) | 2005-07-28 | 2007-02-01 | Doney John A | Amorphous efavirenz and the production thereof |
| US7803818B2 (en) * | 2005-12-21 | 2010-09-28 | Eisai R&D Management Co., Ltd. | Amorphous form of 1,2-dihydropyridine compound |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| WO2007092642A2 (en) | 2006-02-09 | 2007-08-16 | Merck & Co., Inc. | Polymer formulations of cetp inhibitors |
| MX2008015686A (es) * | 2006-06-06 | 2009-01-12 | Tibotec Pharm Ltd | Procedimiento para preparar formulaciones secadas por aspersion de etravirina. |
| US8834929B2 (en) | 2006-07-21 | 2014-09-16 | Bend Research, Inc. | Drying of drug-containing particles |
| WO2008080037A2 (en) | 2006-12-21 | 2008-07-03 | Isp Investments Inc. | Carotenoids of enhanced bioavailability |
| JP5508859B2 (ja) | 2007-01-26 | 2014-06-04 | アイエスピー インヴェストメンツ インコーポレイテッド | 噴霧乾燥製品を製造するための調剤処理方法 |
| EP2046777A2 (en) | 2007-05-01 | 2009-04-15 | Plus Chemicals B.V. | Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide |
| US20100048524A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| CN102686600A (zh) | 2009-02-05 | 2012-09-19 | 托凯药业股份有限公司 | 甾体cyp17抑制剂/抗雄激素物质的新型药物前体 |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| PT3130396T (pt) | 2009-03-27 | 2021-05-12 | Bend Res Inc | Processo de secagem por pulverização |
| CN104922071A (zh) | 2010-04-09 | 2015-09-23 | 帕西拉制药有限公司 | 用于配制大直径合成膜囊泡的方法 |
| CN103002880B (zh) | 2010-06-09 | 2015-01-28 | Abbvie公司 | 含有激酶抑制剂的固态分散体 |
| EP2585048B1 (en) * | 2010-06-23 | 2018-04-11 | CymaBay Therapeutics, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| EP2611529B1 (en) | 2010-09-03 | 2019-01-23 | Bend Research, Inc. | Spray-drying method |
| EP2611530B1 (en) | 2010-09-03 | 2019-01-16 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
| EP2618924A1 (en) | 2010-09-24 | 2013-07-31 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| CN103429228B (zh) | 2011-01-05 | 2016-10-26 | 赫士睿股份有限公司 | 万古霉素的喷雾干燥 |
| TWI590821B (zh) * | 2011-01-18 | 2017-07-11 | 輝瑞有限公司 | 固體分子分散液 |
| PT106063B (pt) * | 2011-12-19 | 2017-05-30 | Inst Superior Tecnico | Minociclina cristalina termorresistente produzida por recristalização com dióxido de carbono |
| AU2013226076B2 (en) | 2012-02-27 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
| CN109078015A (zh) * | 2012-05-31 | 2018-12-25 | 默沙东公司 | 食欲素受体拮抗剂的固体剂量制剂 |
| ES2892029T3 (es) * | 2012-09-11 | 2022-02-01 | Medivation Prostate Therapeutics Llc | Formulaciones de enzalutamida |
| EA029081B9 (ru) | 2013-01-31 | 2018-09-28 | Джилид Фармассет Ллс | Комбинированный состав двух противовирусных соединений |
| CA2899032A1 (en) | 2013-02-01 | 2014-08-07 | Glialogix, Inc. | Compositions and methods for the treatment of neurodegenerative and other diseases |
| CA2904170A1 (en) | 2013-03-14 | 2014-09-25 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| JP2016528252A (ja) | 2013-08-12 | 2016-09-15 | トーカイ ファーマシューティカルズ， インコーポレイテッド | アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| CN103694903B (zh) * | 2013-12-02 | 2015-07-01 | 南通瑞普埃尔生物工程有限公司 | 一种瞬干胶粘剂及其制备方法 |
| EP3076951B1 (en) * | 2013-12-05 | 2020-09-30 | Celal Albayrak | Process for the production of drug formulations for oral administration |
| ES3009527T3 (en) * | 2014-07-25 | 2025-03-27 | Laurent Pharmaceuticals | Solid oral formulation of fenretinide |
| US10406127B2 (en) | 2014-07-25 | 2019-09-10 | Laurent Pharmaceuticals | Solid oral formulation of fenretinide |
| KR20170063954A (ko) | 2014-10-07 | 2017-06-08 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정 |
| EP3212169B1 (en) | 2014-10-31 | 2021-01-13 | Bend Research, Inc. | Process for forming active domains dispersed in a matrix |
| MA41107B1 (fr) * | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals, Inc. | Compositions anti-cancéreuses |
| LT3226843T (lt) | 2014-12-05 | 2021-08-10 | Aragon Pharmaceuticals, Inc. | Priešvėžinės kompozicijos |
| RU2585023C1 (ru) * | 2014-12-18 | 2016-05-27 | Общество с ограниченной ответственностью "Нанолек" | Способ гранулирования |
| CA2987867C (en) | 2015-06-09 | 2023-06-27 | Capsugel Belgium Nv | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules |
| BR112018071048A2 (pt) | 2016-04-15 | 2019-05-07 | Janssen Sciences Ireland Uc | combinações e métodos que compreendem um inibidor da montagem de capsídeos |
| GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
| US20180110760A1 (en) | 2016-10-21 | 2018-04-26 | Glialogix, Inc. | Compositions and methods for the treatmentof neurodegenerative and other diseases |
| BR112020018601A2 (pt) | 2018-03-14 | 2020-12-29 | Janssen Sciences Ireland Unlimited Company | Regime de dosagem de modulador de montagem de capsídeo |
| TW202019416A (zh) | 2018-07-30 | 2020-06-01 | 日商中外製藥股份有限公司 | 乙內醯脲衍生物的固體分散體 |
| US20200147032A1 (en) | 2018-11-14 | 2020-05-14 | Robert K. Prud'homme | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
| US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
| JP2022554352A (ja) * | 2019-11-06 | 2022-12-28 | マンカインド コーポレイション | クロファジミンの組成物、それを含む組合せ、その調製プロセス、それを含む使用及び処置方法 |
| KR20250057151A (ko) | 2019-12-30 | 2025-04-28 | 데시페라 파마슈티칼스, 엘엘씨 | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의조성물 |
| PT4084779T (pt) | 2019-12-30 | 2024-11-06 | Deciphera Pharmaceuticals Llc | Composições de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-di-hidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilureia |
| AU2020419197B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| MX2023003556A (es) | 2020-09-29 | 2023-06-13 | Shenzhen Pharmacin Co Ltd | Composiciones farmaceuticas. |
| JP2025512788A (ja) * | 2022-03-25 | 2025-04-22 | シェンチェン ファーマシン シーオー．，エルティーディー． | Ｐｒｏｔａｃ化合物の医薬組成物及びその使用 |
| WO2024143501A1 (ja) | 2022-12-28 | 2024-07-04 | 中外製薬株式会社 | 分散対象物質を含む固体分散体、それを含む医薬組成物及びそれらの製造方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1131242A (en) | 1965-02-18 | 1968-10-23 | Gen Foods Ltd | Improvements in or relating to spray-drying apparatus |
| GB1329791A (en) | 1971-01-19 | 1973-09-12 | Niro Atomizer As | Spray drying devices for the production of powder eg milk powder |
| IT1025765B (it) | 1974-11-18 | 1978-08-30 | Gastaldi Francesco | Essiccatore perfezionato a spruzzo |
| DE2741196A1 (de) * | 1977-09-13 | 1979-03-15 | Bayer Ag | Verfahren zur herstellung von perlpolymeren |
| US4187617A (en) | 1978-12-18 | 1980-02-12 | Becker James J Jr | Spray dryer |
| US4702799A (en) | 1985-09-03 | 1987-10-27 | Nestec S.A. | Dryer and drying method |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| NZ283160A (en) | 1994-05-06 | 1998-07-28 | Pfizer | Azithromycin in a controlled release dosage form for treating microbiol infections |
| US5958458A (en) * | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| DE19613691A1 (de) * | 1996-04-05 | 1997-10-09 | Boehringer Ingelheim Int | Arzneimittel für die Behandlung von Tumorerkrankungen |
| US5858409A (en) * | 1996-04-17 | 1999-01-12 | Fmc Corporation | Hydrolyzed cellulose granulations for pharmaceuticals |
| PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
| EP1027887B1 (en) | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
| DE60042352D1 (de) | 1999-02-10 | 2009-07-23 | Pfizer Prod Inc | Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten |
| EP1027886B1 (en) | 1999-02-10 | 2008-07-09 | Pfizer Products Inc. | Pharmaceutical solid dispersions |
| US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| AR027656A1 (es) | 2000-03-16 | 2003-04-09 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| UY26615A1 (es) * | 2000-03-16 | 2001-10-25 | Pfizer Prod Inc | Inhibidor de la glucogeno fosforilasa. |
| US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| WO2003063822A2 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| PL371593A1 (en) | 2002-02-01 | 2005-06-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
-
2003
- 2003-01-20 PL PL03371593A patent/PL371593A1/xx not_active Application Discontinuation
- 2003-01-20 MX MXPA04007435A patent/MXPA04007435A/es active IP Right Grant
- 2003-01-20 EP EP20030700071 patent/EP1469830A2/en not_active Withdrawn
- 2003-01-20 KR KR1020047011807A patent/KR100758045B1/ko not_active Expired - Fee Related
- 2003-01-20 WO PCT/IB2003/000120 patent/WO2003063821A2/en not_active Ceased
- 2003-01-20 CA CA002474958A patent/CA2474958A1/en not_active Abandoned
- 2003-01-20 BR BR0307515-0A patent/BR0307515A/pt not_active IP Right Cessation
- 2003-01-20 RS YU67304A patent/RS67304A/sr unknown
- 2003-01-20 JP JP2003563515A patent/JP2005523260A/ja active Pending
- 2003-01-20 RU RU2004123639/04A patent/RU2288703C2/ru not_active IP Right Cessation
- 2003-01-20 AU AU2003239463A patent/AU2003239463B2/en not_active Ceased
- 2003-01-20 CN CNA038047640A patent/CN1787808A/zh active Pending
- 2003-01-24 US US10/351,568 patent/US7780988B2/en active Active
- 2003-01-28 TW TW092101817A patent/TW200404576A/zh unknown
- 2003-01-29 PE PE2003000096A patent/PE20030804A1/es not_active Application Discontinuation
- 2003-01-30 GT GT200300024A patent/GT200300024A/es unknown
- 2003-01-30 AR ARP030100268A patent/AR038369A1/es unknown
- 2003-01-31 UY UY27645A patent/UY27645A1/es not_active Application Discontinuation
- 2003-02-03 PA PA20038565401A patent/PA8565401A1/es unknown
-
2004
- 2004-07-27 ZA ZA200405971A patent/ZA200405971B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8565401A1 (es) | 2003-12-10 |
| ZA200405971B (en) | 2006-05-31 |
| KR100758045B1 (ko) | 2007-09-11 |
| MXPA04007435A (es) | 2004-10-11 |
| RU2288703C2 (ru) | 2006-12-10 |
| EP1469830A2 (en) | 2004-10-27 |
| AU2003239463B2 (en) | 2007-10-18 |
| RS67304A (sr) | 2006-10-27 |
| GT200300024A (es) | 2003-09-22 |
| KR20040083491A (ko) | 2004-10-02 |
| US7780988B2 (en) | 2010-08-24 |
| WO2003063821A3 (en) | 2003-11-13 |
| PL371593A1 (en) | 2005-06-27 |
| UY27645A1 (es) | 2003-09-30 |
| WO2003063821A2 (en) | 2003-08-07 |
| US20030185893A1 (en) | 2003-10-02 |
| BR0307515A (pt) | 2004-12-07 |
| TW200404576A (en) | 2004-04-01 |
| PE20030804A1 (es) | 2003-09-19 |
| JP2005523260A (ja) | 2005-08-04 |
| CN1787808A (zh) | 2006-06-14 |
| RU2004123639A (ru) | 2005-04-20 |
| CA2474958A1 (en) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038369A1 (es) | Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion y producto | |
| Yuan et al. | Preparation of self-assembled nanoparticles of ε-polylysine-sodium alginate: a sustained-release carrier for antigen delivery | |
| Sultanova et al. | Controlled release of a hydrophilic drug from coaxially electrospun polycaprolactone nanofibers | |
| Thote et al. | Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release | |
| Wenk et al. | Silk fibroin spheres as a platform for controlled drug delivery | |
| RU2318495C2 (ru) | Способы распылительной сушки для получения твердоаморфных дисперсий лекарственных средств и полимеров | |
| Freitas et al. | Ultrasonic atomisation into reduced pressure atmosphere—envisaging aseptic spray-drying for microencapsulation | |
| CA2944283C (en) | Improved spray drying process for production of powders with enhanced properties | |
| US20230094393A1 (en) | Peptide particles and methods of formation | |
| Paudel et al. | An investigation into the effect of spray drying temperature and atomizing conditions on miscibility, physical stability, and performance of naproxen–PVP K 25 solid dispersions | |
| CN1088092A (zh) | 微颗粒制剂及其生产方法 | |
| KR20100117601A (ko) | 전기분사법에 의한 패취의 제조방법 | |
| Wen et al. | Preparation and characterization of protein-loaded electrospun fiber mat and its release kinetics | |
| CN101568328A (zh) | 基于两性分子共聚物和活性成分的改性释放的微颗粒以及含有它们的药物制剂 | |
| CN102198102A (zh) | 一种载药微球的制备方法 | |
| Man et al. | High voltage electrohydrodynamic atomization of bovine lactoferrin and its encapsulation behaviors in sodium alginate | |
| Clarke et al. | Influence of formulation variables on the morphology of biodegradable micropartieles prepared by spray drying | |
| CN115066519A (zh) | 静电纺丝天然聚合物的方法 | |
| Soares et al. | A novel globular protein electrospun fiber mat with the addition of polysilsesquioxane | |
| Saallah et al. | Transformation of cyclodextrin glucanotransferase (CGTase) from aqueous suspension to fine solid particles via electrospraying | |
| Montaño-Grijalva et al. | Preparation and Characterization of Zein-Metformin/Gelatin Nanofibers by Coaxial Electrospinning | |
| Zorec et al. | Particle properties and drug metastable solubility of simvastatin containing PVP matrix particles prepared by electrospraying technique | |
| KR102564095B1 (ko) | 폴리(락티드-코-글리콜리드) 공중합체 미세입자의 제조 방법 | |
| Hadlock et al. | Biologic activity of nerve growth factor slowly released from microspheres | |
| CN106562931A (zh) | 一种短链脂肪酸囊泡的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |